Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin as Add-on to Metformin in T2DM
NCT03259789Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Theracos, Inc. Primary endpoint: Change From Baseline in HbA1c at Week 24. Started Nov 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03259789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259789.